Enzalutamide
- Generic Name
- Enzalutamide
- Brand Names
- Xtandi, Enzalutamide Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16F4N4O2S
- CAS Number
- 915087-33-1
- Unique Ingredient Identifier
- 93T0T9GKNU
- Background
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012. Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieve...
- Indication
Enzalutamide is indicated for the treatment of castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer (mCRPC). It is also used in combination with talazoparib for the treatment of adult patients with HRR gene-mutated mCRPC.
- Associated Conditions
- Castration Resistant Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Associated Therapies
- -
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
- Conditions
- Interventions
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 424
- Registration Number
- NCT01977651
- Locations
- 🇦🇺
Site AU61011, Sydney, New South Wales, Australia
🇺🇸Site US10039, Syracuse, New York, United States
🇺🇸Site US10008, Dallas, Texas, United States
Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
- Conditions
- Interventions
- First Posted Date
- 2013-11-03
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 59
- Registration Number
- NCT01974765
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1311
- Registration Number
- NCT01949337
- Locations
- 🇺🇸
Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States
🇺🇸University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
- Conditions
- Interventions
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 69
- Registration Number
- NCT01946165
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-09-16
- Last Posted Date
- 2022-10-24
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 67
- Registration Number
- NCT01942837
- Locations
- 🇺🇸
South Shore Hospital, Weymouth, Massachusetts, United States
🇺🇸University of Washington Medical Center/Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Enzalutamide in Patients With High-risk Prostate Cancer
- First Posted Date
- 2013-08-22
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT01927627
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-06-28
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 118
- Registration Number
- NCT01889238
- Locations
- 🇺🇸
Rocky Mountain Cancer Center Sky Ridge, Lone Tree, Colorado, United States
🇺🇸Texas Oncology - Memorial City, Houston, Texas, United States
🇺🇸Florida Cancer Specialist South Division, Fort Myers, Florida, United States
Tivozanib + Enzalutamide in Adv Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-06-25
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT01885949
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
- First Posted Date
- 2012-08-14
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 396
- Registration Number
- NCT01664923
- Locations
- 🇺🇸
Alliance Urology Specialists, PA, Greensboro, North Carolina, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸UCLA Clark Urology Clinic, Los Angeles, California, United States
A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-08-13
- Last Posted Date
- 2012-09-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Registration Number
- NCT01663415
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.